<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9372">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05699239</url>
  </required_header>
  <id_info>
    <org_study_id>TS172-02-01</org_study_id>
    <nct_id>NCT05699239</nct_id>
  </id_info>
  <brief_title>A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis</brief_title>
  <official_title>A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in&#xD;
      hyperphosphatemia patients on hemodialysis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2023</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in serum concentration of phosphorus</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement ratio of patients with the target serum concentration of phosphorus</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of corrected serum calcium</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium times phosphorus product</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hyperphosphatemia Patients on Hemodialysis</condition>
  <arm_group>
    <arm_group_label>10 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive TS-172 10 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive TS-172 30 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive TS-172 60 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive TS-172 20 mg tid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-172 10mg bid</intervention_name>
    <description>oral administration of TS-172 10 mg bid</description>
    <arm_group_label>10 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-172 30mg bid</intervention_name>
    <description>oral administration of TS-172 30 mg bid</description>
    <arm_group_label>30 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-172 60mg bid</intervention_name>
    <description>oral administration of TS-172 60 mg bid</description>
    <arm_group_label>60 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-172 20mg tid</intervention_name>
    <description>oral administration of TS-172 20 mg tid</description>
    <arm_group_label>20 mg tid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hyperphosphatemia patients (outpatients) with chronic kidney disease receiving&#xD;
             hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to Visit 1 (Week&#xD;
             -4)&#xD;
&#xD;
          2. Patients aged ≥18 to &lt;80 years at the time of obtaining informed consent&#xD;
&#xD;
          3. Patients with a serum phosphorus concentration of ≥ 3.5 mg/dL and ≤ 6.0 mg/dL at Visit&#xD;
             1 (Week -4)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with confirmed serum intact PTH concentration &gt;500 pg/mL from Visit 1 (Week&#xD;
             -4) to Visit 5 (Week 0)&#xD;
&#xD;
          2. Patients with serum phosphorus concentration ≥ 10.0 mg/dL from Visit 2 (Week -3) to&#xD;
             Visit 5 (Week 0)&#xD;
&#xD;
          3. Patients who have undergone previous parathyroid intervention (PTx, PEIT, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Director</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taisho Pharmaceutical Co., Ltd.</last_name>
    <phone>81-3-3985-1118</phone>
    <email>clinical-trials_CTG@taisho.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taisho Director</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 12, 2023</study_first_submitted>
  <study_first_submitted_qc>January 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>February 9, 2023</last_update_submitted>
  <last_update_submitted_qc>February 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

